Source-gap reconciliation: an October 23 primary release and simultaneous Lancet online paper on PANKU-Breast01 were absent from the reviewed Insilens report history. In this China Phase III trial, izalontamab brengitecan prolonged blinded-review PFS versus…
FDA approved imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, detected by an FDA-authorized test, after progression on at least one endocrine-therapy line. FDA simultaneously approved Guardant360 CDx…
Circle Pharma closed an oversubscribed $92.5 million Series E led by The Column Group, with Nextech Invest, RA Capital Management, Euclidean Capital and a strategic investment from Eli Lilly. The company plans to advance…
The European Commission approved AstraZeneca’s Etcamah, or camizestrant, with a CDK4/6 inhibitor for adults with ER-positive, HER2-negative advanced breast cancer when an ESR1 mutation emerges during first-line aromatase-inhibitor plus CDK4/6 therapy but before disease…
Genentech entered a breast cancer drug discovery collaboration with Astex Pharmaceuticals worth up to $490 million in milestones, while Fierce Biotech reported that 103 roles were affected as part of Genentech Research and Early…
